Small Stocks, Big Money™

Gorilla Technology Group (Nasdaq: GRRR) strengthened its financial position with a $6 million capital injection from warrant exercises, bolstering its balance sheet and supporting its strategic share buyback initiatives. With a robust project pipeline, key partnerships, and a focus on AI-driven solutions in high-growth markets like smart cities and cybersecurity, Gorilla is well-positioned to drive long-term growth and deliver value to stakeholders.

BullFrog AI (Nasdaq: BFRG) closed 2024 with significant progress, advancing its AI-driven bfLEAP™ platform, forging impactful collaborations like its breakthrough work with the Lieber Institute for Brain Development, and expanding research on its promising assets such as BF-114 for liver disease. With a strong leadership team, enhanced IP portfolio, and $8.83 million in new funding, the company is poised to drive growth and achieve significant milestones in 2025.

Mobilicom Limited (Nasdaq: MOB) bolstered its balance sheet with $1.2 million in cash proceeds from recent warrant exercises, extending its cash runway to at least 24 months. With revenues tripling and operating efficiencies improving in 2024, the company is poised for continued growth in the high-demand drone and robotics market. CEO Oren Elkayam highlighted strong market dynamics and increasing adoption of Mobilicom’s cybersecure solutions, setting the stage for a promising 2025.

60 Degrees Pharmaceuticals (Nasdaq: SXTP) and Tufts Medical Center signed a Patent License Agreement to co-develop and commercialize tafenoquine for babesiosis, a serious tick-borne disease. The collaboration includes joint patent ownership, exclusive commercialization rights for 60 Degrees, and ongoing research led by Tufts. Currently in clinical trials, tafenoquine has potential as the first prophylactic treatment for babesiosis, addressing a critical unmet need for patients with limited options and coinfections like Lyme disease.